Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,accountsPayable,treasuryStock,otherStockholderEquity,deferredLongTermLiab,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,priceHint,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,GRAY,84562000.0,21055900,6448000,,-11449000,,-11449000,5040000,0,-11488000,-11488000,,,,,,0,0,11488000,0,39000,,-11449000,-11449000,229376000.0,6290000.0,84562000.0,494000.0,90852000.0,2000.0,-144816000.0,12000.0,29000.0,10589000.0,6278000.0,2002000.0,88821000.0,75099000.0,1956000.0,,,,-13521000.0,-508000.0,-13657000.0,92000.0,1406000.0,92000.0,-22829000.0,-9264000.0,118000.0,1169000.0,-136000.0,,82543000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,4.43,1630526403,0.049999714,4.4,4.49,4.255,203985,"Graybug Vision, Inc.",NGM,PREPRE,-0.3232973,0,False,False,-2.934529,1630539948,4.3,-0.12999964,1.1415459,4.255 - 4.49,4.38,0.0,0.0,8,9,finmb_142651139,NasdaqGM,"Graybug Vision, Inc.",USD,2059667,221128,0.99999976,0.29154512,3.43 - 37.88,-33.45,-0.88305175,3.43,37.88,1614891600,1614891600,1614891600,4,-1.67,-2.6526945,4.048,0.38199997,0.094367586,6.546449,-2.1164494,93277632,15,America/New_York,EDT,-14400000,,,,37.88,3.43,4.048,6.5464,2.06M,221.13k,21.06M,,7.8M,10.47%,70.68%,1.99M,0.61,17.27%,9.46%,1.56M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.00%,-55.21%,,,,,-33.1M,-37.08M,,,85.69M,4.07,,,14.15,,-30.62M,,Value,94065,Healthcare,32,10,9,"Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.",Redwood City,650 487 2800,CA,8,1609372800,1622505600,6,United States,http://www.graybug.vision,86400,9,275 Shoreline Drive,Biotechnology,Suite 450
t-1,GRAY,94786000.0,21055900,5488000,,-9152000,,-9152000,3687000,0,-9175000,-9175000,,,,,,0,0,9175000,0,23000,,-9152000,-9152000,228155000.0,7008000.0,94786000.0,401000.0,101794000.0,2000.0,-133367000.0,11000.0,608000.0,33418000.0,6997000.0,1946000.0,99240000.0,61615000.0,2513000.0,-4000.0,-4000.0,,-61637000.0,-258000.0,-62463000.0,10684000.0,-1277000.0,12555000.0,-61550000.0,-9771000.0,111000.0,805000.0,-826000.0,-1871000.0,92243000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,4.43,1630526403,0.049999714,4.4,4.49,4.255,203985,"Graybug Vision, Inc.",NGM,PREPRE,-0.3232973,0,False,False,-2.934529,1630539948,4.3,-0.12999964,1.1415459,4.255 - 4.49,4.38,0.0,0.0,8,9,finmb_142651139,NasdaqGM,"Graybug Vision, Inc.",USD,2059667,221128,0.99999976,0.29154512,3.43 - 37.88,-33.45,-0.88305175,3.43,37.88,1614891600,1614891600,1614891600,4,-1.67,-2.6526945,4.048,0.38199997,0.094367586,6.546449,-2.1164494,93277632,15,America/New_York,EDT,-14400000,,,,37.88,3.43,4.048,6.5464,2.06M,221.13k,21.06M,,7.8M,10.47%,70.68%,1.99M,0.61,17.27%,9.46%,1.56M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.00%,-55.21%,,,,,-33.1M,-37.08M,,,85.69M,4.07,,,14.15,,-30.62M,,Value,94065,Healthcare,32,10,9,"Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.",Redwood City,650 487 2800,CA,8,1609372800,1622505600,6,United States,http://www.graybug.vision,86400,9,275 Shoreline Drive,Biotechnology,Suite 450
t-2,GRAY,90634000.0,21055900,4757000,,-4716000,,-4716000,2064000,0,-6821000,-6821000,,,,,,0,0,6821000,0,2105000,,-4716000,-7112000,214847000.0,7751000.0,90634000.0,594000.0,98385000.0,2000.0,-124215000.0,10000.0,1491000.0,94968000.0,7741000.0,1788000.0,95106000.0,,4562000.0,,,,-61637000.0,501000.0,-43000.0,82829000.0,300000.0,83754000.0,77426000.0,-5360000.0,96000.0,-1541000.0,-43000.0,-925000.0,87365000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,4.43,1630526403,0.049999714,4.4,4.49,4.255,203985,"Graybug Vision, Inc.",NGM,PREPRE,-0.3232973,0,False,False,-2.934529,1630539948,4.3,-0.12999964,1.1415459,4.255 - 4.49,4.38,0.0,0.0,8,9,finmb_142651139,NasdaqGM,"Graybug Vision, Inc.",USD,2059667,221128,0.99999976,0.29154512,3.43 - 37.88,-33.45,-0.88305175,3.43,37.88,1614891600,1614891600,1614891600,4,-1.67,-2.6526945,4.048,0.38199997,0.094367586,6.546449,-2.1164494,93277632,15,America/New_York,EDT,-14400000,,,,37.88,3.43,4.048,6.5464,2.06M,221.13k,21.06M,,7.8M,10.47%,70.68%,1.99M,0.61,17.27%,9.46%,1.56M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.00%,-55.21%,,,,,-33.1M,-37.08M,,,85.69M,4.07,,,14.15,,-30.62M,,Value,94065,Healthcare,32,10,9,"Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.",Redwood City,650 487 2800,CA,8,1609372800,1622505600,6,United States,http://www.graybug.vision,86400,9,275 Shoreline Drive,Biotechnology,Suite 450
t-3,GRAY,-102954000.0,21055900,6085000,,-7794000,,-7794000,1711000,0,-7796000,-7796000,,,,,,0,0,7796000,0,2000,,-7794000,-9093000,3341000.0,7198000.0,-102954000.0,2684000.0,22404000.0,1000.0,-119499000.0,,2959000.0,17542000.0,7198000.0,1781000.0,17664000.0,,2208000.0,,,1418000.0,17000000.0,-380000.0,16853000.0,-840000.0,-2946000.0,11000.0,5302000.0,-10711000.0,93000.0,316000.0,-147000.0,-851000.0,10466000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,4.43,1630526403,0.049999714,4.4,4.49,4.255,203985,"Graybug Vision, Inc.",NGM,PREPRE,-0.3232973,0,False,False,-2.934529,1630539948,4.3,-0.12999964,1.1415459,4.255 - 4.49,4.38,0.0,0.0,8,9,finmb_142651139,NasdaqGM,"Graybug Vision, Inc.",USD,2059667,221128,0.99999976,0.29154512,3.43 - 37.88,-33.45,-0.88305175,3.43,37.88,1614891600,1614891600,1614891600,4,-1.67,-2.6526945,4.048,0.38199997,0.094367586,6.546449,-2.1164494,93277632,15,America/New_York,EDT,-14400000,,,,37.88,3.43,4.048,6.5464,2.06M,221.13k,21.06M,,7.8M,10.47%,70.68%,1.99M,0.61,17.27%,9.46%,1.56M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.00%,-55.21%,,,,,-33.1M,-37.08M,,,85.69M,4.07,,,14.15,,-30.62M,,Value,94065,Healthcare,32,10,9,"Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.",Redwood City,650 487 2800,CA,8,1609372800,1622505600,6,United States,http://www.graybug.vision,86400,9,275 Shoreline Drive,Biotechnology,Suite 450
